Table 1.
Characteristics of four de novo pedAML patients used for the sorting and micro-array profiling of CD34+/CD38+ and CD34+/CD38− cell fractions. Patients were diagnosed in Belgium and classified as standard risk. WT1 overexpression was interpreted in regard to in-house or published (Cilloni et al. 2009) cut-offs.
| Variation | Median (Range) | ||
|---|---|---|---|
| Age, years | 14 (10–15) | ||
| WBC count, ×109 | 79 (58.1–118) | ||
| Morphological blast count | |||
| BM% | 88 (34–95) | ||
| PB% | 74 (38–78) | ||
| N | % | ||
| Gender | |||
| F | 3 | 75.0% | |
| M | 1 | 25.0% | |
| Study protocol | |||
| DB AML-01 | 4 | 100.0% | |
| CNS involvement | 0 | 0.0% | |
| WT1 overexpression | 2 | 50.0% | |
| Fusion transcript | 2 | 50.0% | |
| CBF leukemia | 2 | 50.0% | |
| AML1::ETO + C-KITWT | 1 | 25.0% | |
| AML1::ETO + C-KITMUT | 0 | 0.0% | |
| CBF::MYH11 | 1 | 25.0% | |
| Gene mutation | |||
| NPM1 | 0 | 0.0% | |
| CEBPA | 0 | 0.0% | |
| FLT3 | |||
| ITD | 2 | 50.0% | |
| WT | 2 | 50.0% | |
| Karyotype | |||
| Normal | 1 | 25.0% | |
| Abnormal | 3 | 75.0% | |
| FAB classification | |||
| M0 | 1 | 25.0% | |
| M2 | 1 | 25.0% | |
| M4 | 2 | 50.0% | |